{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:56:50Z","timestamp":1784570210213,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008769","name":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["DFG SCHM 2460\/3-1"],"award-info":[{"award-number":["DFG SCHM 2460\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["DFG SCHM 2460\/3-3"],"award-info":[{"award-number":["DFG SCHM 2460\/3-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020613","name":"Graduate School of Life Sciences, Julius-Maximilians-Universit\u00e4t W\u00fcrzburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020613","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009379","name":"Interdisziplin\u00e4res Zentrum f\u00fcr Klinische Forschung, Universit\u00e4tsklinikum W\u00fcrzburg","doi-asserted-by":"publisher","award":["Z-6"],"award-info":[{"award-number":["Z-6"]}],"id":[{"id":"10.13039\/501100009379","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.neo.2026.101301","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:07:47Z","timestamp":1774930067000},"page":"101301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["AXL is a novel ERK5\/KLF4 target in MEK inhibitor-treated melanoma"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6361-0162","authenticated-orcid":false,"given":"Rupesh","family":"Paudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2694-4950","authenticated-orcid":false,"given":"Simon","family":"Goller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7383-4303","authenticated-orcid":false,"given":"Katharina","family":"Meder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-9848","authenticated-orcid":false,"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8643-1615","authenticated-orcid":false,"given":"Marc","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2026.101301_bib0001","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1158\/1078-0432.CCR-25-0278","article-title":"Facts and hopes: toward the next quantum leap in melanoma","volume":"31","author":"Flaherty","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101301_bib0002","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1101\/gad.329771.119","article-title":"Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities","volume":"33","author":"Rambow","year":"2019","journal-title":"Genes Dev."},{"key":"10.1016\/j.neo.2026.101301_bib0003","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-025-00603-8","article-title":"Cutaneous melanoma","volume":"11","author":"Tasdogan","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.neo.2026.101301_bib0004","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.jid.2020.03.972","article-title":"Efficient suppression of NRAS-driven melanoma by Co-inhibition of ERK1\/2 and ERK5 MAPK pathways","volume":"140","author":"Adam","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.neo.2026.101301_bib0005","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/0008-5472.CAN-18-2762","article-title":"Resistance to MAPK inhibitors in melanoma involves activation of the IGF1R-MEK5-Erk5 pathway","volume":"79","author":"Benito-Jardon","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2026.101301_bib0006","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/1873-3468.14960","article-title":"The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib","volume":"598","author":"Mondru","year":"2024","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neo.2026.101301_bib0007","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41419-025-08036-7","article-title":"MEK5\/ERK5 inhibition sensitizes NRAS-mutant melanoma to MAPK-targeted therapy by preventing cyclin D\/CDK4-mediated G1\/S progression","volume":"16","author":"Paudel","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neo.2026.101301_bib0008","article-title":"Targeting BMK1 impairs the drug resistance to combined inhibition of BRAF and MEK1\/2 in melanoma","volume":"7","author":"Song","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neo.2026.101301_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11551","article-title":"ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1\/2 abrogation","volume":"7","author":"de Jong","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2026.101301_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199264","article-title":"A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC","volume":"13","author":"Dompe","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neo.2026.101301_bib0011","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ccell.2018.10.001","article-title":"KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism","volume":"34","author":"Vaseva","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2026.101301_bib0012","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1158\/2767-9764.CRC-21-0089","article-title":"Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1\/S cell cycle transition","volume":"2","author":"Zhang","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.neo.2026.101301_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147594","article-title":"The MEK5\/ERK5 pathway in health and disease","volume":"22","author":"Paudel","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neo.2026.101301_bib0014","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nbt1374","article-title":"Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts","volume":"26","author":"Nakagawa","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neo.2026.101301_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1597210","article-title":"Kruppel-like factor 4 control of immune cell function","volume":"16","author":"Das","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2026.101301_bib0016","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4049\/jimmunol.1101530","article-title":"Kruppel-like factors in lymphocyte biology","volume":"188","author":"Hart","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.neo.2026.101301_bib0017","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc3582","article-title":"Kruppel-like factors in cancer","volume":"13","author":"Tetreault","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neo.2026.101301_bib0018","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1152\/physrev.00058.2009","article-title":"Mammalian Kruppel-like factors in health and diseases","volume":"90","author":"McConnell","year":"2010","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neo.2026.101301_bib0019","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/ncb1314","article-title":"The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene","volume":"7","author":"Rowland","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.neo.2026.101301_bib0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/cvr\/cvu236","article-title":"Erk5 inhibits endothelial migration via KLF2-dependent down-regulation of PAK1","volume":"105","author":"Komaravolu","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.neo.2026.101301_bib0021","doi-asserted-by":"crossref","first-page":"26199","DOI":"10.1074\/jbc.M110.103127","article-title":"Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4)","volume":"285","author":"Ohnesorge","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neo.2026.101301_bib0022","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fcvm.2018.00006","article-title":"Kruppel-like factors in vascular inflammation: mechanistic insights and therapeutic potential","volume":"5","author":"Sweet","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.neo.2026.101301_bib0023","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bone.2018.03.020","article-title":"The MEK5\/ERK5 mitogen-activated protein kinase cascade is an effector pathway of bone-sustaining bisphosphonates that regulates osteogenic differentiation and mineralization","volume":"111","author":"Adam","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.neo.2026.101301_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143509","article-title":"ERK5 is a major determinant of chemical sarcomagenesis: implications in human pathology","volume":"14","author":"Arconada-Luque","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2026.101301_bib0025","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1042\/BCJ20210646","article-title":"An ERK5-KLF2 signalling module regulates early embryonic gene expression and telomere rejuvenation in stem cells","volume":"478","author":"Brown","year":"2021","journal-title":"Biochem. J."},{"key":"10.1016\/j.neo.2026.101301_bib0026","doi-asserted-by":"crossref","first-page":"8553","DOI":"10.1128\/MCB.25.19.8553-8566.2005","article-title":"Transcriptional regulation of tissue-specific genes by the ERK5 mitogen-activated protein kinase","volume":"25","author":"Sohn","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.neo.2026.101301_bib0027","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.devcel.2010.12.005","article-title":"ERK5 regulates muscle cell fusion through Klf transcription factors","volume":"20","author":"Sunadome","year":"2011","journal-title":"Dev. Cell"},{"key":"10.1016\/j.neo.2026.101301_bib0028","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neo.2026.101301_bib0029","doi-asserted-by":"crossref","first-page":"W171","DOI":"10.1093\/nar\/gkz365","article-title":"CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing","volume":"47","author":"Labun","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neo.2026.101301_bib0030","doi-asserted-by":"crossref","first-page":"45608","DOI":"10.18632\/oncotarget.10058","article-title":"KLF4alpha stimulates breast cancer cell proliferation by acting as a KLF4 antagonist","volume":"7","author":"Ferralli","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2026.101301_bib0031","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1053\/j.gastro.2010.08.022","article-title":"KLF4alpha up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer","volume":"139","author":"Wei","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neo.2026.101301_bib0032","doi-asserted-by":"crossref","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neo.2026.101301_bib0033","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-023-00846-8","article-title":"Therapeutic targeting of the functionally elusive TAM receptor family","volume":"23","author":"Miao","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neo.2026.101301_bib0034","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","article-title":"A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors","volume":"4","author":"Konieczkowski","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2026.101301_bib0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.neo.2026.101301_bib0036","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ccr.2010.08.008","article-title":"Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein","volume":"18","author":"Yang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2026.101301_bib0037","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccell.2015.03.010","article-title":"AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR\/PKC\/mTOR axis in head and neck and esophageal squamous cell carcinomas","volume":"27","author":"Elkabets","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.neo.2026.101301_bib0038","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neo.2026.101301_bib0039","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1038\/onc.2015.434","article-title":"ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT","volume":"35","author":"Debruyne","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2026.101301_bib0040","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"Muller","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2026.101301_bib0041","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nm.4472","article-title":"Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF\/MEK inhibitors","volume":"24","author":"Boshuizen","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2026.101301_bib0042","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1021\/acschembio.7b00638","article-title":"Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains","volume":"13","author":"Wang","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.neo.2026.101301_bib0043","doi-asserted-by":"crossref","first-page":"11865","DOI":"10.1073\/pnas.1609019113","article-title":"ERK5 kinase activity is dispensable for cellular immune response and proliferation","volume":"113","author":"Lin","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neo.2026.101301_bib0044","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/jid.2011.218","article-title":"Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase","volume":"131","author":"Sensi","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.neo.2026.101301_bib0045","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1158\/0008-5472.CAN-18-2316","article-title":"Cross-talk between receptor tyrosine kinases AXL and ERBB3 regulates invadopodia formation in melanoma cells","volume":"79","author":"Revach","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2026.101301_bib0046","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1038\/onc.2016.481","article-title":"KLF4 is regulated by RAS\/RAF\/MEK\/ERK signaling through E2F1 and promotes melanoma cell growth","volume":"36","author":"Riverso","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2026.101301_bib0047","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-12-256446","article-title":"KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma","volume":"116","author":"Guan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.neo.2026.101301_bib0048","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3892\/or.2017.5708","article-title":"KLF2 inhibits cell growth via regulating HIF-1alpha\/Notch-1 signal pathway in human colorectal cancer HCT116 cells","volume":"38","author":"Wang","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.neo.2026.101301_bib0049","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"AXL signaling in cancer: from molecular insights to targeted therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neo.2026.101301_bib0050","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/0008-5472.CAN-20-0434","article-title":"Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade","volume":"81","author":"Boshuizen","year":"2021","journal-title":"Cancer Res."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:30:06Z","timestamp":1776814206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558626000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"alternative-id":["S1476558626000308"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2026.101301","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AXL is a novel ERK5\/KLF4 target in MEK inhibitor-treated melanoma","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2026.101301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101301"}}